ArticleCureus2026
A Rare Presentation of Pulmonary Transthyretin Amyloidosis With Persistent Ground-Glass Opacity Diagnosed by Transbronchial Lung Biopsy.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary-dominant transthyretin (TTR) amyloidosis is an uncommon condition. Its presentation with persistent ground-glass opacity (GGO) and infiltrates mimics common respiratory diseases, causing diagnostic delays. Here, we report a case of an 80-year-old male patient with a five-year history of GGO refractory to antibiotics and steroids. Endobronchial ultrasound-guided transbronchial lung biopsy confirmed TTR amyloidosis. Investigations revealed subclinical cardiac involvement, supporting systemic amyloid TTR (ATTR) with a pulmonary-dominant phenotype. Treatment with tafamidis was initiated; however, pulmonary lesions remained radiologically stable at two months and at one year of follow-up. Given that tafamidis is expected to stabilize TTR and slow disease progression rather than rapidly regress established deposits, short-term radiologic stability should be interpreted cautiously. This case demonstrates the diagnostic utility of minimally invasive bronchoscopic techniques for unexplained lung opacities and highlights the need for further evidence regarding the clinical course and treatment response of pulmonary manifestations of ATTR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.